Prečo pouţiť rivaroxaban v liečbe HŢT? MUDr. Ivan Čupka
|
|
- Rafe Melton
- 5 years ago
- Views:
Transcription
1 Prečo pouţiť rivaroxaban v liečbe HŢT? MUDr. Ivan Čupka HŢT Hlboká ţilová trombóza L.SK.MA
2 Potenciálny konflikt záujmov MUDr. Ivan Čupka Konzultant farmaceutických spoločností Člen Advisory Board spoločností Iná spolupráca (konkretizovať aká) so spoločnosťami: prednášková činnosť Bayer
3 Klinické štúdie a reálna klinická prax Registračné štúdie t Viac ako 9,000 HŢT/PE pacientov zaradených do randomizovaných kontrolovaných štúdií Prvá medzinárodná, prospektívna observačná štúdia na NOAK t Viac ako 5,000 HŢT pacientov sledovaných v rutinnej klinickej praxi Hodnotené v širokom spektre pacientov v študijnom programe HŢT/PE 1 1.Prins M.H., Lensing A.W.A., Bauersachs R. et al. Thrombosis J. 2013;11(1):21., 2. Bauersachs R.M., Berkowitz S.D., Brenner B. et al. N Engl J Med. 2010;363(26): , 3. Ageno W., Mantovani L.G., Haas S., et al. Thrombosis J. 2014;12(1):16., NOAK Perorálne antikoagulanciá okrem antagonistu vitamínu K
4 Cieľ t zber reálnych dát u pacientov s akútnou HŢT liečených rivaroxabanom alebo štandardnou antikoagulačnou liečbou Pacienti s diagnostikovanou akútnou HŢT* a s indikáciou na antikoagulačnú liečbu 3 mesiace Typ, dávka a trvanie pouţívanej liečby je na zváţení ošetrujúceho lekára Rivaroxaban na 3 mesiace Investigátori zhromaţďovali dáta pri prvej návšteve, po 1. mesiaci a potom štvrťročne # (1 mesiac po ukončení liečby) Štandardná antikoagulačná liečba napr. iniciálna liečba LMWH/fondaparinuxom, pokračujúca s VKA alebo parenterálna antikoagulačná liečba na 3 mesiace Finálne hodnotenie Primárne ciele Udalosti závaţného krvácania, symptomatická recidivujúca VTE a všetky príčiny smrti HŢT hlboká ţilová trombóza, LMWH nízkomolekulový heparín, VTE venózny tromboembolizmus, VKA anatgonista vitamínu K ClinicalTrials.gov NCT ; *After PE EU licence, DVT with concomitant PE permitted; isolated PE excluded. # Data were collected at the initial visit and during routine follow-up visits or via mail, telephone, or Ageno W et al, Published online December 7, 2015.
5 Inklúzne / Exklúzne kritériá Inklúzne kritériá Muţi alebo ţeny, vek pacientov 18 rokov s akútnou HŢT s indikáciou na antikoagulačnú liečbu na 3 mesiace Po schválení rivaroxabanu pre indikáciu PE, boli zaradení pacienti s HŢT a súbeţne PE Exklúzne kritériá Pacienti s izolovanou PE Ďalšie exklúzne kritériá boli v súlade s lokálnymi indikačnými obmedzeniami 1,Ageno W et al, Published online December 7, 2015, DVT hlboká ţilová trombóza, PE pľúcna embólia.
6 Charakteristika pacientov je podobná so štúdiou EINSTEIN HŢT 1,2 Vek (roky, priemer +/- štandardná odchýlka) CrCl<30 ml/min (%) Predchádzajúca VTE, n (%) Aktívne onkologické ochorenie n (%) 55,8 +/- 16,4 57,3 +/- 16,7 (1,0) (24,0) (6,0) 993 (57,4) (55) DVT - Hlboká ţilová trombóza, VTE - Venózny tromboembolizmus, CrCL - klírens kreatinínu, n- počet 1. Ageno W et al, Thromb J. 2014;12: Bauersachs R.M., Berkowitz S.D., Brenner B. et al. N Engl J Med. 2010;363(26):
7 (%) (%) Účinnosť a výskyt závaţných krvácaní 1 Štúdia fázy III. s rivaroxabanom vs. LMWH/VKA Prospektívna, neintervančná štúdia s rivaroxabanom a štandardnou antikoagulačnou liečbou v beţnej praxi * Závaţné krvácanie Rekurencia VTE Celková mortalita Závaţné krvácanie Rekurencia VTE Celková mortalita rivaroxaban rivaroxaban DVT hlboká ţilová trombóza, VTE venózny tromboembolizmus, VKA antagonista vitamínu K *Propensity score-adjusted population. 1. Ageno W et al, Published online December 7, 2015.
8 Rekurencia symptomatického VTE (%) Účinná liečba HŢT/PE u pacientov s ľahkou a stredne ťaţkou poruchou funkcie obličiek a,1 CrCL ml/min CrCL ml/min CrCL ml/min CrCL <15 ml/min PE pľúcna embólia, DVT hlboká ţilová trombóza, VTE venózny tromboembolizmus, CrCl klírens kreatinínu,vka antagonista vitamínu K, CrCl Klírens kreatinínu, a,normálna funkcia obličiek: CrCl 80 ml/min. Ľahká porucha funkcie obličiek: CrCl ml/min. Stredne ťaţká porucha funkcie obličiek: CrCl ml/min. Ťaţká porucha funkcie obličiek: CrCl ml/min. #redukcia dávky z 20 mg jeden krát denne na 15 mg jeden krát denne by mala byť zváţená ak riziko krvácania u pacienta prevaţuje riziko rekurencie DVT and PE 1, Bauersachs R.M., Lensing A.W.A., Prins M.H. et al. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J. 2014;12:25.
9 Závaţné krvácania (%) Niţší výskyt závaţných krvácaní u pacientov a,1,4 s ľahkou a stredne ťaţkou poruchou funkcie obličiek rivaroxaban PE pľúcna embólia, DVT hlboká ţilová trombóza, RRR relatívna redukcia rizika, ARR absolútna redukcia rizika, CrCl klírens kreatinínu, VKA antagonista vitamínu K, a,normálna funkcia obličiek: CrCl 80 ml/min. Ľahká porucha funkcie obličiek: CrCl ml/min. Stredne ťaţká porucha funkcie obličiek: CrCl ml/min. 1, Bauersachs R.M., Lensing A.W.A., Prins M.H. et al. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J. 2014;12: Prins M.H., Lensing A.W.A., Bauersachs R. et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11(1):21
10 Aké máme dôkazy v liečbe DVT u pacientov s aktívnym onkologickým ochorením rivaroxaban PE pľúcna embólia, DVT hlboká ţilová trombóza, LMWH nízkomolekulový heparín, VKA antagonista vitamínu K 1. Prins M.H., Lensing A.W.A., Brighton T.A. et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014;1(1):e37 e36 5. Lee A.Y.,Levine M.N., Baker R.I., et al. Low molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2): Agnelli G., Büller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9): Büller H.R., Décousus H., Grosso M.A., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15): Schulman S., Kearon C., Kakkar A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24): Schulman S., Kakkar A.K. Goldhaber S.Z., et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circ. 2014;129(7):
11 Rekurencia symptomatického VTE (%) Závaţné krvácanie (%) Rivaroxaban výskyt rekurencie VTE a závaţného krvácania pri liečbe DVT/PE a,1 rivaroxaban rivaroxaban PE pľúcna embólia, DVT hlboká ţilová trombóza, VTE venózny tromboembolizmus, VKA antagonista vitamínu K, RRR relatívna redukcia rizika, ARR absolútna redukcia rizika. a) Podskupina analyzovaných pacientov s aktívnym nádorom zaradených v EINSTEIN DVT a EINSTEIN PE randomizovaných kontrolovaných štúdiách 1. Prins M.H., Lensing A.W.A., Brighton T.A. et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014;1(1):e37 e36
12 Výskyt recidívy VTE (%)* Riziko rekurencie VTE je najvyššie v prvých 3-4 týţdňoch VTE Venózny tromboembolizmus 3,Adaptované podľa Limone B.L., et al. 2013, *príhody rekurencie VTE paciento/rok A literature search of MEDLINE, EMBASE and CENTRAL during April 2013 identified randomised trials of acute pharmacologic treatment and prevention of recurrent VTE, enrolling 200 subjects/treatment arm, requiring anticoagulation for 3 months and reporting time to objectively confirmed recurrent VTE (n=27,237).
13 Percento pacientov s kompletnou regresiou trombu Kompletná regresia trombu (USG + CT) 70% 60% Rivaroxaban Štandardná liečba Priemerná dĺţka liečby: 50% - rivaroxaban 195 dní - warfarín 200 dní 40% 30% 20% 10% 0% 20/75 (26,7%) DEŇ Day 22 3/19 (15,8%) Dĺţka terapie 44/71 (62%) EOT 6/19 (31,6%) PE pľúcna embólia, DVT hlboká ţilová trombóza, EOT end of intended treatment period na konci plánovaného liečebného obdobia Preddefinovaný výsledok zobrazovania J-Einsteinova populácie (n = 100). Zahŕňa DVT a PE, 1. Yamada N et al, Thromb J 2015;13:2.,
14 Liečba a dlhodobá ochrana pred DVT s rivaroxabanom 1 Od 22. dňa rivaroxaban 15 mg 2 x denne od stanovenia diagnózy DVT rivaroxaban Rivaroxaban 15 mg a 20 mg sa má uţívať s jedlom z dôvodu optimálnej perorálnej biologickej dostupnosti 1 Bez potreby iniciálnej liečby s heparínom 1. Rivaroxaban SPC, Súhrn charakteristických vlastností lieku, Júl 2015, DVT hlboká ţilová trombóza
15 Indikačné obmedzenie v liečbe HŢT Hradená liečba sa môţe indikovať na liečbu hlbokej ţilovej trombózy a prevenciu rekurencie hlbokej ţilovej trombózy a pľúcnej embólie u pacientov s proximálnou (lokalizovaná vo vena poplitea a proximálnejšie) hlbokou ţilovou trombózou,ktorá musí byt objektívne potvrdená (duplexným ultrazvukovým alebo venografickým vyšetrením). Doba uhrádzanej liečby je limitovaná na maximálne: a) 3 mesiace v prípade prvej vyprovokovanej hlbokej ţilovej trombózy, b) 6 mesiacov v prípade idiopatickej hlbokej ţilovej trombózy, c) 12 mesiacov v prípade opakovanej recidivujúcej hlbokej ţilovej trombózy. Pri indikácii podľa písmena c) sa vyţaduje súčasné splnenie aspoň jednej z týchto podmienok: 1. chronická liečba warfarínom nie je dostatočne kontrolovaná v terapeutickom rozmedzí INR 2-3, t.j. dve merania zo šiestich nie sú v takto uvedenom terapeutickom rozmedzí, 2. recidíva hlbokej ţilovej trombózy alebo pľúcnej embólie napriek liečbe warfarínom, 3. liečba warfarínom je kontraindikovaná. HŢT Hlboká ţilová trombóza
16 Ďakujem za pozornosť
17 Podporné slidy
18 Kumulatívna incidencia (%) Kumulatívna incidencia závaţného krvácania 4 Rivaroxaban Štandardná antikoagulácia 3 2 HR=0.41 (95% CI ) Čas do prvej udalosti (dni) 1. Ageno W., Mantovani L., Haas S. et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep vein thrombosis (XALIA): an international prospective non-interventional study. Published online December 7, Populácia bezpečnosti, Upravené pre karcinóm pri vstupe do štúdie
19 Výsledky pre závaţné krvácanie Závaţné krvácanie (posudzované) Rivaroxaban (n=2619) n (%) Štandardná antikoagulácia (n=2149) n (%) 19 (0.7) 48 (2.3) Hazard ratio* (95% CI) 0.41 ( ) Fatálne 0 (0.0) 2 (0.1) Nefatálne do kritických orgánov Intrakraniálne (subdurálne, subarachnoidálne alebo cerebrálne) Nefatálne, iné nekritické miesta Gastrointestinálne krvácanie 8 (0.3) 12 (0.6) 6 (0.2) 5 (0.2) 11 (0.4) 34 (1.6) 3 (0.1) 18 (0.8) 1. Ageno W., Mantovani L., Haas S. et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep vein thrombosis (XALIA): an international prospective non-interventional study. Published online December 7, Populácia bezpečnosti; * Upravené pre karcinóm pri vstupe do štúdie
20 Kumulatívna incidencia (%) 1. Ageno W., Mantovani L., Haas S. et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep vein thrombosis (XALIA): an international prospective non-interventional study. Published online December 7, Populácia bezpečnosti; Upravené pre karcinóm pri vstupe do štúdie Kumulatívna incidencia rekurentného VTE Rivaroxaban Standard Štandardná anticoagulation antikoagulácia 4 3 HR=0.67 (95% CI ) Čas do udalosti (dni)
21 Tromboembolické príhody Rivaroxaban (n=2619) n (%) Štandardná antikoagulácia (n=2149) n (%) Hazard ratio* (95% CI) Rekurentný VTE (posudzovaný) 37 (1.4) 55 (2.6) 0.67 ( ) Fatálna PE 1 (<0.1) 1 (<0 1) Úmrtie kde sa PE nevylúčila 4 (0.2) 4 (0.2) Nefatálna PE 17 (0.6) 17 (0.8) Rekurentná DVT + PE 1 (<0.1) 4 (0.2) Rekurentná DVT 13 (0.5) 30 (1.4) Iné 1 (<0.1) 0 (0.0) 1. Ageno W., Mantovani L., Haas S. et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep vein thrombosis (XALIA): an international prospective non-interventional study. Populácia bezpečnosti; niektorí pacienti mali > 1 tromboembolickú príhodu; * Upravené pre karcinóm pri vstupe do štúdie, VTE Venózny tromboembolizmus, PE Pľúcna embólia, DVT Hlboká ţilová trombóza
22 Kumulatívna incidencia (%) 1. Ageno W., Mantovani L., Haas S. et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep vein thrombosis (XALIA): an international prospective non-interventional study. bezpečnosti; stratifikovaná na karcinóm pri vstupe do štúdie Celková mortalita Rivaroxaban 7 Standard Štandardná anticoagulation antikoagulácia HR=0.26 (95% CI ) Čas do udalosti (dni)
23 Celková mortalita Rivaroxaban (n=2619) n (%) Štandardná antikoagulácia (n=2149) n (%) Hazard ratio* (95% CI) Úmrtia z akýchkoľvek príčin 12 (0.5) 88 (4.1) 0.26 ( ) Súvisiace s VTE 4 (0.2) 4 (0.2) PE 1 (<0.1) 1 (<0.1) PE sa nevylúčila 3 (0.1) 3 (0.1) Súvisiace s krvácaním 0 (0.0) 0 (0.0) Súvisiace s nádorom 6 (0.2) 61 (2.8) Kardiovaskulárne ochorenie 1 (<0.1) 10 (0.5) Iné 1 (<0.1) 13 (0.6) 1. Ageno W., Mantovani L., Haas S. et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep vein thrombosis (XALIA): an international prospective non-interventional study. bezpečnosti; *Stratifikovaná pre karcinóm pri vstupe do štúdie VTE Venózny tromboembolizmus, PE Pľúcna embólia
24 Klinické výsledky Rivaroxaban (n=2505) n (%) Štandardná antikoagulácia (n=2010) n (%) Hazard ratio (95% CI) p-value Závaţné krvácanie 19 (0.8) 43 (2.1) Rekurentný VTE 36 (1.4) 47 (2.3) 0.77 ( ) 0.91 ( ) Úmrtia z akýchkoľvek príčin 11 (0.4) 69 (3.4) 0.51 ( ) Ageno W., Mantovani L., Haas S. et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep vein thrombosis (XALIA): an international prospective non-interventional study. Populácia propensity-skóre analýzy, VTE Venózny tromboembolizmus
25 Signifikantná redukcia dĺţky hospitalizácie 1 t Signifikantná redukcia hospitalizácie o 3 a dni Dĺţka hospitalizácie Analýza rivaroxaban štandardná antikoagulácia V prospech rivaroxabanu V prospech štandardnej antikoagulácie Pred úpravou dát * Po úprave dát * *Priemerná dĺţka pobytu vypočítaná iba z hospitalizovaných pacientov; pomer na základe analýzy ANOVA rozptylu z logaritmicky transformovaných dát LOS. a 3 dni zaokrúhlené nahor od priemerného zníţenia 2,7 dňa, * Pred štatistikcou úpravou dát - PMS propensity score matching 1. Ageno W et al, Published online December 7, 2015.
26 Závaţné krvácania (%) Niţší výskyt závaţných krvácaní u pacientov s ľahkou a stredne ťaţkou poruchou funkcie obličiek a,1,4 rivaroxaban t Celkový výskyt klinicky relevantného nezávaţného krvácania bol porovnávaný medzi rivaroxabanom a štandardnou 1,4 liečbou enoxaparínom + VKA PE pľúcna embólia, DVT hlboká ţilová trombóza, RRR relatívna redukcia rizika, ARR absolútna redukcia rizika, CrCl klírens kreatinínu, VKA antagonista vitamínu K, a,normálna funkcia obličiek: CrCl 80 ml/min. Ľahká porucha funkcie obličiek: CrCl ml/min. Stredne ťaţká porucha funkcie obličiek: CrCl ml/min. 1, Bauersachs R.M., Lensing A.W.A., Prins M.H. et al. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J. 2014;12: Prins M.H., Lensing A.W.A., Bauersachs R. et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11(1):21
Results from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationEvidences for real-life use in fragile patients: Renal failure and cancer
Evidences for real-life use in fragile patients: Renal failure and cancer Cecilia Becattini Medicina Interna e Cardiovascolare Stroke Unit Università di Perugia Approval number: L.IT.MA.11.2016.1839 Evidences
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationNew Perspective in VTE Treatment in Acute Medically Ill Patients: Single vs. Dual Drug Approach. Dr. Johan Kurnianda, SpPD-KHOM
New Perspective in VTE Treatment in Acute Medically Ill Patients: Single vs. Dual Drug Approach Dr. Johan Kurnianda, SpPD-KHOM VTE : Spectrum of Disease Deep Vein Thrombosis Post Thrombotic Syndrome Pulmonary
More informationTreatment of cancer-associated venous thromboembolism by new oral anticoagulants: a meta-analysis
Original Article Page of 9 Treatment of cancer-associated venous thromboembolism by new oral anticoagulants: a meta-analysis Satyanarayana R. Vaidya, Sonu Gupta, Santhosh R. Devarapally, Department of
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationNon commercial use only. The treatment of venous thromboembolism with new oral anticoagulants. Background
Italian Journal of Medicine 2013; volume 7(s8):29-35 The treatment of venous thromboembolism with new oral anticoagulants Davide Imberti AUSL Piacenza, Italy ABSTRACT Traditional anticoagulants, such as
More informationOral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study.
Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study Comments Harald Darius, Berlin Disclosures for Harald Darius Research
More informationSubgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE
THIEME Original Article e33 Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of versus Anticoagulation for VTE Walter Ageno 1 Lorenzo G. Mantovani 2 Sylvia Haas 3 Reinhold
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationThe clinical relevance of AMPLIFY programme
Venice October 16th 2015 The clinical relevance of AMPLIFY programme Francesco Dentali Department of Clinical Medicine Insubria University Varese Disclosures Bayer Bristol-Myers Squibb/Pfizer Boehringer
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationDOACs in CAT. Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD
DOACs in CAT Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD Case 65 year old post menopausal female Left breast lesion Oct 2015 Biopsy Invasive ductal carcinoma Lumpectomy with SNB- pt1cno
More informationFocus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular
More informationΑντιπηκτική αγωγή 2017 Νέες μελέτες, πραγματικά δεδομένα και κλινική πράξη
Αντιπηκτική αγωγή 2017 Νέες μελέτες, πραγματικά δεδομένα και κλινική πράξη Σταύρος Β. Κωνσταντινίδης, MD, PhD, FESC Καθηγητής Καρδιολογίας Δημοκρίτειο Πανεπιστήμιο Θράκης skonst@med.duth.gr Medical Director
More informationWhen and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD
When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD December 12, 2015 Disclosures CONSULTANT Merck; New Haven
More informationABSTRACT INTRODUCTION
Adv Ther (2014) 31:473 493 DOI 10.1007/s12325-014-0119-7 REVIEW Phase III Trials of New Oral Anticoagulants in the Acute Treatment and Secondary Prevention of VTE: Comparison and Critique of Study Methodology
More informationDOACs in SPECIAL POPULATIONS
DOACs in SPECIAL POPULATIONS Ann K Wittkowsky PharmD, CACP, FASHP, FCCP Clinical Professor University of Washington School of Pharmacy Director, Anticoagulation Services UWMedicine Department of Pharmacy
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationIs Oral Rivaroxaban Safe and Effective in the Treatment of Patients with Symptomatic DVT?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 1-1-2013 Is Oral Rivaroxaban Safe and Effective
More informationDirect oral anticoagulants and venous thromboembolism
REVIEW VENOUS THROMBOEMBOLISM Direct oral anticoagulants and venous thromboembolism Massimo Franchini 1 and Pier Mannuccio Mannucci 2 Affiliations: 1 Dept of Transfusion Medicine and Hematology, Carlo
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationI nuovi anticoagulanti orali nella trombosi venosa profonda. Terapia della TVP. Fulvio POMERO. Medicina Interna S. Croce e Carle Cuneo
I nuovi anticoagulanti orali nella trombosi venosa profonda Terapia della TVP Fulvio POMERO Medicina Interna S. Croce e Carle Cuneo 1 2 3 Poor VKA control (first 90 days) Good VKA control (first 90 days)
More informationSpontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren
Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren Paul Kyrle Allgemeines Krankenhaus Wien Disclosures relevant for this presentation Consultancies, member of advisory boards, speaker
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationA Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations
A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations Allison Bernard, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics October 25 th,
More informationDirect Oral Anticoagulants in Patients With VTE and Cancer A Systematic Review and Meta-analysis
[ Original Research Pulmonary Vascular Disease ] Direct Oral Anticoagulants in Patients With VTE and Cancer A Systematic Review and Meta-analysis Maria Cristina Vedovati, MD ; Federico Germini, MD ; Giancarlo
More informationCancer Associated Thrombosis: six months and beyond. Farzana Haque Hull York Medical School
Cancer Associated Thrombosis: six months and beyond Farzana Haque Hull York Medical School Disclosure I have no disclosure The Challenge of Anticoagulation in Patients with Venous Thromboembolism and Cancer
More informationHokusai-VTE: Edoxaban for the treatment of venous thromboembolism
OPEN ACCESS Lessons from the trials Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism Karim Said* Aswan Heart Centre, Aswan, Egypt *Email: kareemsaid@gmail.com ABSTRACT Venous thromboembolism
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationNew areas of development for the direct oral anticoagulants
New areas of development for the direct oral anticoagulants Varese March 2016 Disclosures for Harry R Büller Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory
More informationUSE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY
SDSHP ANNUAL MEETING CLINICAL PEARLS APRIL 7 TH, 2017 USE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY STEFFANIE DANLEY, PHARM D, BCPS, CACP DISCLOSURE I have had no financial relationship over the past 12
More informationReduced-dosed Rivaroxaban in the long-term prevention of recurrent symptomatic DVT The Einstein-Choice trial
Reduced-dosed Rivaroxaban in the long-term prevention of recurrent symptomatic DVT The Einstein-Choice trial Thomas HW Stadlbauer Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar,
More informationAntikoagulačná liečba venózneho tromboembolizmu v špecifických situáciách
Antikoagulačná liečba venózneho tromboembolizmu v špecifických situáciách Juraj Maďarič Klinika kardiológie a angiológie NÚSCH, a LF SZU Bratislava Agenda Onkologickí pacienti Renálna insuficiencia Gravidita
More informationClinical aspects of venous thromboembolism in special patient populations Bleker, S.M.
UvA-DARE (Digital Academic Repository) Clinical aspects of venous thromboembolism in special patient populations Bleker, S.M. Link to publication Citation for published version (APA): Bleker, S. M. (2017).
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationThe DOACs. Update on Anticoagulation 10/20/2017. Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Objectives
Objectives Update on Anticoagulation JEFF REIST PHARMD, BCPS CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF IOWA COLLEGE OF PHARMACY At the conclusion of this program, the participant should be able to: List
More informationA Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism
Cardiol Ther (2018) 7:1 13 https://doi.org/10.1007/s40119-018-0107-0 REVIEW A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism Andrew
More informationNew Anticoagulants and Emerging Strategies
New Anticoagulants and Emerging Strategies in the Treatment of Venous Thromboembolism b Stavros V. Konstantinides, MD, PhD, FESC Head, Department of Cardiology, Democritus University of Thrace, Greece
More informationNovel oral anticoagulants in the treatment of cancer patients
Novel oral anticoagulants in the treatment of cancer patients Renata Biernacka, MD 1, Tomasz Lewandowski, MD PhD 1, Jolanta Andrzejuk, MD 2, Marek Szmyd, MD 1 1 Department of Chemotherapy, Oncology Clinic,
More informationLa terapia del TEV nel paziente oncologico nell'era dei DOAC
XXVI CONGRESSO NAZIONALE FCSA Bologna, 5-7 Novembre 2015 Tromboembolismo venoso La terapia del TEV nel paziente oncologico nell'era dei DOAC ANNA FALANGA Immunoematologia e Medicina Trasfusionale e Centro
More informationPrevention and management of venous thromboembolism M. AAPRO
Prevention and management of venous thromboembolism M. AAPRO Thromboprophylaxisof DVT and PE in AmbulatoryCancerPatients Zurich, February 2017 M. AAPRO Based on a lesson in April 2016 by M. DICATO M.D.,
More informationUpdates in venous thromboembolism. Cecilia Becattini University of Perugia
Updates in venous thromboembolism Cecilia Becattini University of Perugia News for VTE Diagnosis Treatment the acute phase the agents Pulmonary embolism: diagnosis Vein ultrasonography Meta-analysis 15
More informationDOACs and CAT. 05 May 2017 NTW St Thomas Hospital
DOACs and CAT Alexander (Ander) Cohen Vascular Medicine / Haematology Guy s and St Thomas Hospitals, King s College, London 05 May 2017 NTW St Thomas Hospital Disclosures for Dr. Alexander (Ander) T. Cohen
More informationUsing direct oral anticoagulants (DOACs) in cancer and other high-risk populations
EVOLVING ISSUES IN ANTICOAGULATION Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations Nick van Es 1 and Harry R. Büller 1 1 Department of Vascular Medicine, Academic Medical
More informationBenefit risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism
Review Article 231 Benefitrisk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism Jan Beyer-Westendorf 1 ; Walter Ageno 2 1 Center for Vascular Diseases
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationRivaroxaban film coated tablets are available in 2 strengths for this indication: 15mg and 20mg.
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Rivaroxaban is a non-vitamin K antagonist
More informationDirect oral anticoagulants: now also for prevention and treatment of cancer-associated venous thromboembolism?
COMMON CLINICAL QUESTIONS IN CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM Direct oral anticoagulants: now also for prevention and treatment of cancer-associated venous thromboembolism? Ingrid Pabinger and
More informationBlood Day for Primary Care
Blood Day for Primary Care including the Anticoagulation, use of novel oral anticoagulants in DVT/PE & atrial fibrillation Marc Carrier MD MSc. FRCPC Department of Internal Medicine, Division of Hematology,
More informationMy Cancer Patient Has a Clot- Can I prescribe a Direct Oral Anticoagulant (DOAC)?
My Cancer Patient Has a Clot- Can I prescribe a Direct Oral Anticoagulant (DOAC)? November 24, 2018 Erica Peterson MD, FRCPC University of British Columbia Disclosures I participate in clinical research
More informationThe latest on the diagnosis and treatment of venous thromboembolism
The latest on the diagnosis and treatment of venous thromboembolism Vicky Tagalakis MD FRCP Division of General Internal Medicine Jewish General Hospital McGill University Disclosures Advisory board Pfizer
More informationWith All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis
BRIGHAM AND WOMEN S HOSPITAL With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis Gregory Piazza, MD, MS Division of Cardiovascular Medicine Brigham and Women s Hospital April
More informationDiagnosis and Management of Venous Thromboembolism
Diagnosis and Management of Venous Thromboembolism Muhammad Sajid Pervaiz Consultant Haematologist Chairman VTE committee Pennine Acute Hospitals NHS trust TOPICS 1-Introduction (Seriousness of problem)
More informationDiagnostika a liečba relabovaného a refraktérneho DLBCL
Diagnostika a liečba relabovaného a refraktérneho DLBCL Miriam Ladická Národný onkologický ústav Vysoká účinnosť Akceptovateľná Liečba ochorenia toxicita Minimálne neskoré NÚ cca 1/3 pacientov s DLBCL
More informationThe Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for
The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for Anticoagulation Services Sanford USD Medical Center Sioux Falls,
More informationVenous thromboembolic disease is a common cause of
ATVB in Focus Clinical Experience With the Novel Oral Anticoagulants Clinical Experience With the New Oral Anticoagulants for Treatment of Venous Thromboembolism Farzana Bacchus, Sam Schulman Abstract
More informationRespiratory Review of 2014: Pulmonary Thromboembolism
REVIEW http://dx.doi.org/10.4046/trd.2014.77.3.105 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2014;77:105-110 Respiratory Review of 2014: Pulmonary Thromboembolism Jae Seung Lee, M.D. Department
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationNew and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants
Anticoagulation Focus on Direct Oral Anticoagulants Tzu-Fei Wang, MD Assistant Professor Department of Internal Medicine Division of Hematology The Ohio State University Wexner Medical Center Objectives
More informationUC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE
Updates in the Management of Venous Thromboembolism Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic Venous Thromboembolism
More informationAbstract. Background. Methods
Abstract Background Malignancy is a major risk factor for developing venous thromboembolism (VTE), and thus cancer patients are at high risk for deep vein thrombosis (DVT) and/or pulmonary embolism (PE).
More informationScylla a Charibdis: riziká
Scylla a Charibdis: riziká tromboembolizmu a krvácania Ako bezpečne kormidlovať liečbu NOAK u fragilných pacientov s nevalvulárnou fibriláciou predsiení a žilovou tromboembolickou chorobou? doc. MUDr.
More informationStatus of anticoagulation therapy in 2016: Is there a need for venous revascularization?
Status of anticoagulation therapy in 2016: Is there a need for venous revascularization? Rupert M. Bauersachs Dept. of Vascular Medicine, Darmstadt Center of Thrombosis Hemostasis, Mainz Status of anticoagulation
More informationDALLA REAL LIFE INTERNAZIONALE A QUELLA ITALIANA: ESPERIENZE DAL CAMPO
RIVAROXABAN DALLA REAL LIFE INTERNAZIONALE A QUELLA ITALIANA: ESPERIENZE DAL CAMPO Giuseppe Camporese, MD Azienda Ospedaliera Universitaria di Padova Dipartimento di Scienze Cardiache, Toraciche e Vascolari
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationSupplementary Online Content
Supplementary Online Content Caldeira D, Canastro M, Barra M, et al. Risk of substantial intraocular bleeding with novel oral anticoagulants: systematic review and meta-analysis. JAMA Ophthalmol. Published
More informationJeffrey I. Weitz 1,3,4, Iqbal H. Jaffer 2,4, James C. Fredenburgh 1,4
REVIEW Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants [version 1; referees: 2 approved] Jeffrey I. Weitz 1,3,4, Iqbal H. Jaffer 2,4, James C. Fredenburgh
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationAn Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London
An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations
More informationOdporúčania odborných spoločností Zuzana Pribulová
Odporúčania odborných spoločností Zuzana Pribulová Mnohé odborné spoločnosti sa zaoberajú prevenciou a liečbou VTE IUA (International Union of Angiology), 2007 ASCO (American Society of Clinical Oncology),
More informationAkútne koronárne syndrómy
Braunwald E et al. J Am Coll Cardiol 2000;36:970 1062. Akútne koronárne syndrómy Akútny koronárny syndróm Bez elevácie ST segm. Elevácia ST segm. IM bez elevácie ST Nestabilná AP Infarkt myokardu bez Q
More informationKeynote lecture: Oral anticoagulation and DVT
Keynote lecture: Oral anticoagulation and DVT What is the evidence? Is there a need to anticoagulate every lower leg DVT? Disclosure Speaker name:...sebastian Schellong... I have the following potential
More informationExpanding the treatment options of Superficial vein thrombosis with Rivaroxaban
Expanding the treatment options of Superficial vein thrombosis with Rivaroxaban Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Faculty of Medicine, School of Health
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationIntHeartJ January 2018 COMPARISON OF DOACs AND WARFARIN IN CHRONIC DVT
CLINICAL STUDY Comparison of Direct Oral Anticoagulants and Warfarin in the Treatment of Deep Venous Thrombosis in the Chronic Phase A Large, Single-Center, Observational Study Shingo Wakakura, 1 MD, Fumihiko
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationAnticoagulation: a GP primer on the new oral anticoagulants
Cardiology David Brieger Jenny Curnow Anticoagulation: a GP primer on the new oral anticoagulants Background The acceptability of warfarin has been limited by mandatory laboratory monitoring. A number
More informationNew oral anticoagulants: their role and future
HAEMATOLOGY AND ONCOLOGY Clinical Medicine 2013, Vol 13, No 6: s53 s57 New oral anticoagulants: their role and future Susie Shapiro and Mike Laffan ABSTRACT After 60 years in which warfarin has been the
More informationRapid Fire-Top Articles You Need to Know
Rapid Fire-Top Articles You Need to Know TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE- SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE
More informationAcute and long-term treatment of PE. Cecilia Becattini University of Perugia
Acute and long-term treatment of PE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE What is the optimal acute phase treatment for the patient? Intravenous thrombolysis One
More informationComparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding
ORIGINAL CONTRIBUTION Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding Jeffrey A. Kline, MD, David Jimenez, MD,
More informationDuration of anticoagulation
Duration of anticoagulation P. Fontana Service d angiologie et d hémostase Hôpitaux Universitaires de Genève Pomeriggio formativo in coagulazione, Bellinzona, 19.10.2017 Conflict of interest AstraZeneca,
More informationSupplementary Online Content
Supplementary Online Content Huang W-Y, Singer DE, Wu Y-L, et al. Association of intracranial hemorrhage risk with non vitamin K antagonist oral anticoagulant use vs aspirin use: a systematic review and
More informationVTE ACHIEVEMENTS AND CHALLENGES: 2012 AND BEYOND Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s
VTE ACHIEVEMENTS AND CHALLENGES: 2012 AND BEYOND Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine Harvard Medical School October
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationOral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience
Original Article Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience Clinical and Applied Thrombosis/Hemostasis 2017,
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationTreatment of venous thromboembolism: focus on patient characteristics and bleeding complications Brekelmans, M.P.A.
UvA-DARE (Digital Academic Repository) Treatment of venous thromboembolism: focus on patient characteristics and bleeding complications Brekelmans, M.P.A. Link to publication Citation for published version
More informationUpdates in Management of Venous Thromboembolic Disease
Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures
More informationCancer Associated Thrombosis An update.
Cancer Associated Thrombosis An update. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway LIQUID
More informationTechnology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta341
Apixaban for the treatment and secondary prevention ention of deep vein thrombosis and/or pulmonary embolism Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta341 NICE 2017. All
More informationA BS TR AC T. BACKGROUND Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism.
The new england journal of medicine established in 82 august 29, 23 vol. 369 no. 9 Oral for the Treatment of Acute Venous Thromboembolism Giancarlo Agnelli, M.D., Harry R. Buller, M.D., Ph.D., Alexander
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationManagement of Cancer Associated VTE
Management of Cancer Associated VTE Jean M. Connors, MD 2017 Master Class Course Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Assistant Professor of Medicine HMS
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationThe Evidence Base for Treating Acute DVT
The Evidence Base for Treating Acute DVT Mr Chung Sim Lim Consultant Vascular Surgeon and Honorary Lecturer Royal Free London NHS Foundation Trust and University College London NIHR UCLH Biomedical Research
More information